Clinical Trial Update: BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation [Phase 2]

View source ↗

Summary

Phase 2 study evaluating pulsatile LGX818 (encorafenib) in BRAFV600-mutant melanoma (stage IV or unresectable stage III) completed with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• LGX818 (encorafenib)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Melanoma | Phase 2 | Status: COMPLETED | Results posted: 2017-07-24